Home » About the AACR » Newsroom »
David A. Tuveson, MD, PhD, FAACR, inaugurated as President PHILADELPHIA — The American Association for Cancer Research (AACR) welcomes...
PHILADELPHIA – Men who had a high genetic risk of developing prostate cancer were less likely to develop a...
PHILADELPHIA – A combination of copanlisib (Aliqopa) and rituximab led to a 48 percent reduction in the risk of...
PHILADELPHIA – Tumor mutational burden (TMB) was an accurate predictor of response to treatment with immune checkpoint inhibitors for...
PHILADELPHIA – A liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic...
PHILADELPHIA – Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and showed potential...
PHILADELPHIA – Preclinical experiments using cell lines, genetic mouse models, and human pancreatic tumor tissue identified the transcription factor...
PHILADELPHIA – Racial differences in genetic mutations were observed among early-onset colorectal cancers (CRC), according to data presented during...
PHILADELPHIA – Treatment with unselected autologous tumor infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma,...
PHILADELPHIA – Compared with available standard therapies, including immune checkpoint inhibitors, treatment with the bispecific fusion protein tebentafusp nearly...